Investigator Sponsored Studies

Supporting Investigator Research

Click Here to Apply for Investigator Sponsored Study (ISS) Support

Alkermes seeks to support research designed and conducted by independent clinicians and scientists. Alkermes has supported more than 40 clinical trials since the beginning of the ISS program in 2008. Alkermes can provide ARISTADA® (aripiprazole lauroxil), ARISTADA INITIO® (aripiprazole lauroxil) or VIVITROL® (naltrexone for extended release injectable suspension) to the ISS programs it supports. In addition, there may be financial support available. The ISS research Alkermes supports must be based in the U.S. and is typically conducted by experienced researchers who have an established history of successfully receiving independent funding. If you intend to request study drug only and are seeking funding from a source outside Alkermes, we strongly recommend you submit a concept to Alkermes for review before submitting your funding request.

Areas of Interest

Substance Use Disorders

  • Improving treatment initiation and adherence in AUD/OUD
  • Long-term treatment outcomes, including real world data in AUD/OUD
  • Neurologic profile of early recovery in OUD, including but not limited to sleep, cognition, and craving
  • Digital technologies for assessment of physiological parameters (e.g. wearables) and/or treatment access and outcomes (e.g. telehealth) in AUD/OUD
  • Implementing medication for AUD in healthcare systems


  • Reduction in social burden (e.g. family, treatment team) through use of LAIs
  • Demonstration of LAI benefits in specific comorbidities of schizophrenia (e.g. persistent substance problems) or subpopulations (e.g. persons with schizophrenia over the age of 60)
  • Short-term and long-term economic and clinical outcomes of LAI treatment in schizophrenia using real-world data
  • Outcomes research in schizophrenia and LAI use supporting continuity of care utilizing telehealth or other innovative technology-based approaches

ISS applications are reviewed by a cross functional team of medical and scientific staff to consider patient safety, operational feasibility, scientific merit, and alignment with Alkermes research goals and needs. Applications can be submitted in one of two ways:

Please be aware that Alkermes cannot guarantee support for ISS program applications and all decisions regarding such support will be made at Alkermes’ sole discretion. ISS submissions are accepted on a rolling submission basis.

Request for Proposals (RFPs)

There are currently no open RFPs.

Submission Process

Alkermes Pathways Research Awards®

  • Early career investigators seeking funding for research focusing on AUD, OUD, schizophrenia or bipolar disorder may also be interested in the Alkermes Pathways Research Awards, an annual research grant program. Click here for more information.